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COMMENT
Untangling the evolutionary roots of
lung cancer
Siddhartha Devarakonda1,2,3 & Ramaswamy Govindan1,2,3
The genomic and host factors that drive the progression of pre-invasive lesions
in non-small cell lung cancer are poorly understood. Studying these factors can
advance our knowledge of lung cancer biology, aid in the development of better
screening strategies and improve patient outcomes.
Early detection of lung cancer
Lung cancer is one of the leading causes of cancer related mortality1. Nearly 85% of patients with
lung cancer are diagnosed with non-small cell lung cancer (NSCLC), of which lung adeno-
carcinoma (LUAD) and squamous cell carcinoma (SQCC) are the commonly diagnosed sub-
types. A majority of patients with NSCLC are diagnosed with metastatic disease at presentation.
Screening high-risk patients (deﬁned by the National Lung Screening Trial as current smokers or
those who quit smoking within 15 years, aged 55–74 years, with a 30 pack-year smoking history)
for lung cancer through annual low-dose CT (LDCT) scanning is associated with a reduction in
lung cancer related mortality2,3. Nearly two-thirds of the cancers identiﬁed in these screening
studies were stage I cancers, which are potentially curable through resection. However, LDCT
screening is associated with a high false positive rate, suggesting the need for combining imaging
with other strategies, such as molecular testing, to improve screening efﬁciency, decrease costs,
and minimize procedural risks associated with conﬁrmatory biopsies. While pre-invasive lesions
in NSCLC have been well described, not much is known about their biology and factors that
drive their progression to cancer. This knowledge can help develop screening strategies aimed at
identifying pre-invasive lesions at high risk for progression and offer an opportunity for early
intervention.
Pre-invasive lung cancer lesions
The airway epithelium is heterogeneous and consists of different cell types. The ﬁnal histology of
a lung cancer is probably determined by both the cell from which cancer arises and speciﬁc
molecular alterations that drive transformation4. Pre-invasive lesions have been described for
both LUADs and SQCCs. Atypical adenomatous hyperplasia (AAH) and Adenocarcinoma-in-
situ (AIS) are recognized as pre-invasive lesions for LUAD5. AAHs have been incidentally
identiﬁed in the lung parenchyma adjacent to 5–23% of resected LUADs5. These lesions
represent a localized proliferation of atypical appearing type 2 alveolar and club cells and
measure <0.5 cm. AIS is a term used to describe neoplastic cells growing along pre-existing
alveolar structures (lepidic pattern) and measure <3 cm. Unlike AIS, lesions that demonstrate a
focus of invasion measuring <0.5 cm are described as minimally invasive adenocarcinomas
(MIA). AAH and AIS appear as ground glass opacities on CT imaging, while MIAs additionally
https://doi.org/10.1038/s41467-019-10879-6 OPEN
1 Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, United States. 2 Siteman Cancer Center, St. Louis, MO
63110, United States. 3These authors contributed equally; Siddhartha Devarakonda, Ramaswamy Govindan. Correspondence and requests for materials
should be addressed to R.G. (email: rgovindan@wustl.edu)
NATURE COMMUNICATIONS |         (2019) 10:2979 | https://doi.org/10.1038/s41467-019-10879-6 |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
demonstrate a solid component. These lesions likely constitute a
continuum along which pre-invasive lesions progress to LUAD.
Similarly, low and high-grade squamous dysplasia and
carcinoma-in-situ have been described as pre-invasive lesions
for SQCC.
Surgical removal of pre-invasive lesions is associated with
100% 5-year survival. However, identifying these lesions is chal-
lenging and interventions aimed at their removal can be fairly
invasive. Furthermore, data from longitudinal studies indicate
that as many as 54% of pre-invasive lesions can regress without
progressing to cancer, while 0.8–39% of lesions can progress to
cancer depending on the grade of dysplasia6,7. It is therefore,
crucial to gain a thorough understanding of the molecular fea-
tures predicting progression for developing effective therapeutic
strategies and avoiding over-treatment.
The ability of a pre-invasive lesion to successfully establish
invasive disease is likely determined by a variety of tumor
intrinsic and host factors. While some of the processes that drive
progression are shared between LUAD and SQCC, other pro-
cesses tend to be sub-type speciﬁc. For instance, SQCCs appear to
be characterized by early acquisition of 3q gain and loss of
expression of NKX2-1, a lineage survival oncogene for LUAD,
while LUADs select for alterations that activate RTK/RAS sig-
naling8. Large scale next-generation sequencing studies, have
elegantly demonstrated the ability of whole-exome and multi-
regional sequencing to display the clonal architecture of a cancer
and deduce the sequence in which cancer cells acquire genomic
alterations9,10. Together, data from these and other similar stu-
dies have highlighted several common themes in the evolution of
NSCLC10–12. For instance, alterations in genes such as TP53,
KRAS, EGFR and BRAF occur early in the course of tumor
evolution. Nearly, three-quarters of lung cancers undergo genome
duplication, which probably allows them to withstand and pro-
pagate additional genomic instability. NSCLCs often acquire
mutations in other genes crucial for malignant transformation,
such as those regulating chromatin remodeling, histone methy-
lation, and DNA damage response, later in the course of their
evolution. NSCLCs also demonstrate heterogeneity in the muta-
tional processes that drive tumor evolution. Owing to the
mutagenic effect of cigarette smoke, clonal alterations in smoking
related lung cancer are typically enriched for C > A transversions,
while sub-clonal mutations show C > T transitions driven by
APOBEC (cytidine deaminases) enzymes and/or aging related
spontaneous deamination. Limited data of such nature exists for
pre-invasive lesions.
Genomic features of pre-invasive lesions and LUADs
Now, Hu and colleagues report on results from multiregional,
whole-exome sequencing of pre-invasive lesions and LUADs13.
Results from this study demonstrate that mutation burden
increases as lesions in the airway progress from AAH to invasive
disease. This is reﬂected both in the increase of clonal and sub-
clonal mutations. As expected, this increase appeared more
notable in smokers compared to never-smokers. Mutagenic
processes driven by smoking, DNA repair defects, aging asso-
ciated C > T deamination, and APOBEC, appeared to be opera-
tional in pre-invasive lesions. Enrichment for APOBEC driven
mutagenesis was observed as lesions progressed from AAH to
LUAD, suggesting that these enzymes play a key role in lung
cancer, apart from driving sub-clonal diversiﬁcation once the
disease is established. Additionally, increasing copy number
instability and allelic imbalance were also features of malignant
progression. These results are in agreement with observations
made in pre-invasive lesions that progress to SQCC, with pro-
gressive accumulation of mutations and chromosomal instability
playing an important role in the establishment of invasive
disease8.
Chromosomal instability, the progressive accumulation of copy
number changes, and allelic imbalance confer several growth
advantages to cancer cells. In SQCC, upregulation of genes
driving chromosomal instability was found in progressive dys-
plastic lesions8. Large scale genomic analyses utilizing multiple
cancer samples suggest that activating oncogenic mutations can
themselves drive allelic imbalance by favoring loss of wild type
alleles or gain of mutant alleles14. Alternately, some cancers
evolve and acquire oncogenic mutations and copy number
changes separately, with cells co-opting these alterations to pro-
duce a mutant allele dosage that confers a survival advantage.
Evading host immunity
Allelic imbalance plays an important role in tumor immune
evasion. Data from the TRACERx study demonstrates that loss of
heterozygosity (LOH) of either maternal or paternal HLA alleles
is seen in nearly 40% of NSCLCs15. HLA LOH is enriched in
metastatic lesions and the allele that is lost, is often the allele that
is predicted to bind neo-epitopes that are generated from sub-
clonal mutations. Considering that HLA LOH was associated
with features reported to be characteristic of progressive malig-
nant transformation by Hu and colleagues, such as a high sub-
clonal mutation burden and APOBEC mutagenesis, it is likely
that processes such as chromosomal instability and allelic
imbalance play a key role in aiding the progression of pre-
invasive lesions and sub-clonal diversiﬁcation. Finally, recent
observations also suggest that chromosomal instability plays an
important role in metastatic dissemination16. The importance of
acquiring alterations that enable immune evasion in airway pre-
invasive lesions was also demonstrated in a recent analysis pub-
lished by Beane and colleagues17. RNA-sequencing of pre-
malignant airway lesions and brushings of normal appearing
bronchial mucosa in patients undergoing lung cancer screening,
showed progressive/persistent pre-malignant dysplastic lesions to
be associated with a “Proliferative subtype” signature that is
characterized by decreased expression of interferon signaling and
antigen presentation pathway genes and depletion of adaptive
and innate immune cells, when compared to regressive lesions.
Notably, the presence of the proliferative gene signature in nor-
mal appearing bronchial brushings was able to predict for pre-
sence of proliferative pre-malignant lesions elsewhere in the
airway.
Overall, these data suggest that pre-cancerous lesions in the
airway undergo a series of complex changes with common pat-
terns including a progressive accumulation of mutations driven
by deregulation of APOBECs, copy number changes, immune
evasion and selection of alterations that drive RAS/RTK pathway
activation, which is a hallmark feature of most LUADs. It is likely
that some of these processes are inter-linked. For instance, apart
from driving mutagenesis, APOBEC enzymes are capable of
promoting chromosomal instability by inducing DNA replication
stress18. Furthermore, as shown by Hu and colleagues, the evo-
lutionary trajectory of LUAD appears to differ between smokers
and never-smokers13.
Future directions in identifying pre-invasive lesions
These ﬁndings open several possibilities for clinical application.
For instance, therapeutic strategies that target APOBEC muta-
genesis are now being actively studied and it is likely that these
strategies could play an important role in chemo-prevention.
Identifying speciﬁc clonal alterations that are acquired early
during malignant transformation and are critical for transfor-
mation, can aid screening—potentially through the integration of
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imaging with diagnostic approaches such as cell free DNA testing.
Results from the large, multicenter, observational, Circulating
Cell-free Genome Atlas (CCGA) study is likely to shed more light
on the utility of this approach in aiding early cancer detection
(NCT02889978). Identifying key clonal alterations will also pro-
vide us the ability to test approaches that can potentially harness
host immunity for targeting pre-invasive disease. Integrating
clinical and multi-dimensional “—omic” data can help develop
scoring systems that are capable of identifying pre-invasive
lesions most likely to progress to malignancy, to safely direct
invasive therapies8. Finally, a systematic study of oncogenic
pathways that are activated by allelic imbalance is likely to aid in
the discovery of therapeutic targets that are active in pre-invasive
and established invasive disease19.
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